Pemetrexed Disodium for Injection

Disodium N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamate

It is indicated for combined use with cisplatin for the treatment of inoperable malignant pleural mesothelioma.

Pemetrexed should be used under the guidance of a qualified physician who has experience in the application of anti-tumor chemotherapy. Pemetrexed can only be used for intravenous infusion, and the preparation of its solution must follow the instructions for "Preparation of intravenous infusion solution". Malignant pleural mesothelioma

The adverse reaction data of this product are all from data obtained from foreign clinical studies. The following table lists the statistical results of the frequency and severity of adverse reactions greater than 5% in 168 patients with malignant pleural mesothelioma who were randomly treated with pemetrexed and cisplatin combination therapy and 163 patients with malignant pleural mesothelioma who received cisplatin monotherapy in clinical studies. In both trial groups, patients who had not previously received chemotherapy were supplemented with adequate folic acid and vitamin B12. System Organ Frequency Events* Pemetrexed/Cisplatin Cisplatin (N=168) (N=163) All% 3-4 degrees% All% 3-4 degrees% Blood and lymphatic system abnormalitiesNon

It is contraindicated in patients with a history of severe allergic reaction to pemetrexed or other ingredients of the drug.

Precautions for children: null Precautions for pregnancy and lactation: null Precautions for the elderly: null

Chemotherapeutic drugs - Cisplatin does not change the pharmacokinetics of pemetrexed, and pemetrexed has no effect on the pharmacokinetics of all platinum drugs. Vitamins - Concurrent administration of oral folic acid and intramuscular vitamin B12 does not change the pharmacokinetics of pemetrexed. Cytochrome P450 enzymes on drug metabolism - In vitro studies on liver microsomal proteins showed that pemetrexed did not lead to a decrease in the clearance of drugs metabolized by CYP3A enzymes, CYP2D6 enzymes, CYP2C9 enzymes, and CYP1A2 enzymes. No studies have been conducted to observe the effects of pemetrexed on cytochrome P450 isoenzymes. Because, if the recommended dosing schedule (once every 21 days) is followed, pemetrexed has no significant induction effect on any enzyme. Aspirin - Administer low to moderate doses (every 6 hours

0.1g (calculated as C20H21N5O6)

Simcere Pharmaceutical Co., Ltd.

• Founded in:

  1998-09-10

• Address:

  No. 99, Huakang Road, Jiangbei New District, Nanjing, Jiangsu Province

• Tax NO.:

  91320100135665907G

• Registered Funds:

  1.60281382 million yuan

• Website:

  Log in to view

• Email:

  Log in to view